Literature DB >> 12235078

Which 5-ASA?

S P L Travis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12235078      PMCID： PMC1773399          DOI： 10.1136/gut.51.4.548

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  9 in total

1.  Colorectal cancer prevention in ulcerative colitis: a case-control study.

Authors:  J Eaden; K Abrams; A Ekbom; E Jackson; J Mayberry
Journal:  Aliment Pharmacol Ther       Date:  2000-02       Impact factor: 8.171

2.  Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group.

Authors:  S B Hanauer
Journal:  Inflamm Bowel Dis       Date:  1998-05       Impact factor: 5.325

3.  Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI.

Authors:  H Lochs; M Mayer; W E Fleig; P B Mortensen; P Bauer; D Genser; W Petritsch; M Raithel; R Hoffmann; V Gross; M Plauth; M Staun; L B Nesje
Journal:  Gastroenterology       Date:  2000-02       Impact factor: 22.682

4.  Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.

Authors:  L Staerk Laursen; M Stokholm; K Bukhave; J Rask-Madsen; K Lauritsen
Journal:  Gut       Date:  1990-11       Impact factor: 23.059

5.  Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study.

Authors:  P Marteau; J Crand; M Foucault; J C Rambaud
Journal:  Gut       Date:  1998-02       Impact factor: 23.059

6.  Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group.

Authors:  J R Green; J A Gibson; G D Kerr; E T Swarbrick; A J Lobo; C D Holdsworth; J P Crowe; K J Schofield; M D Taylor
Journal:  Aliment Pharmacol Ther       Date:  1998-12       Impact factor: 8.171

7.  Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis.

Authors:  M G Courtney; D P Nunes; C F Bergin; M O'Driscoll; V Trimble; P W Keeling; D G Weir
Journal:  Lancet       Date:  1992-05-23       Impact factor: 79.321

8.  Distribution of mesalazine enemas in active and quiescent ulcerative colitis.

Authors:  A A van Bodegraven; R O Boer; J Lourens; H A Tuynman; J W Sindram
Journal:  Aliment Pharmacol Ther       Date:  1996-06       Impact factor: 8.171

9.  Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis.

Authors:  P Gionchetti; F Rizzello; A Venturi; C Brignola; M Ferretti; S Peruzzo; M Campieri
Journal:  Aliment Pharmacol Ther       Date:  1997-12       Impact factor: 8.171
  9 in total
  3 in total

Review 1.  Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease.

Authors:  Stefano Sansone; Maria Guarino; Fabiana Castiglione; Antonio Rispo; Francesco Auriemma; Ilaria Loperto; Matilde Rea; Nicola Caporaso; Filomena Morisco
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

2.  Hydroalcoholic Extract from Inflorescences of Achyrocline satureioides (Compositae) Ameliorates Dextran Sulphate Sodium-Induced Colitis in Mice by Attenuation in the Production of Inflammatory Cytokines and Oxidative Mediators.

Authors:  Luisa Mota da Silva; Jaime Antonio Machado Farias; Thaise Boeing; Lincon Bordignon Somensi; Ana Paula Beber; Benhur Judah Cury; José Roberto Santin; Sérgio Faloni de Andrade
Journal:  Evid Based Complement Alternat Med       Date:  2016-10-25       Impact factor: 2.629

3.  On the action of 5-amino-salicylic acid and sulfapyridine on M. avium including subspecies paratuberculosis.

Authors:  Robert J Greenstein; Liya Su; Azra Shahidi; Sheldon T Brown
Journal:  PLoS One       Date:  2007-06-13       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.